Xiao Liang

Dr. Xiao Liang

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 November 2014 in Molecules
Verified
Journal Article
Open access
PDF file
RKRavil Khaybullin
Ravil Khaybullin
MZMei Zhang
Mei Zhang
JFJunjie Fu
Junjie Fu
XLXiao Liang
Xiao Liang
TLTammy Li
Tammy Li
XQXin Qi
Xin Qi
One of the keys for successfully developing drugs against the broad spectrum of cancer cell types is structural diversity. In the current study, we focused on a family of isosteviol derivatives as potential novel antitumor agents. Isosteviol is a tetracyclic diterpenoid obtained by acid hydrolysis of steviol glycoside extracts isolated from abundant Stevia rebaudiana plants. In this work, we have designed and synthesized a panel of isosteviol triazole conjugates using “click” chemistry methodology. Evaluation of these compounds against a series of cancer cell lines derived from primary and metastatic tumors demonstrated that these conjugates exhibit cytotoxic activities with IC50 in the low μM range. In addition, their anti-proliferative activities are cancer cell type specific. Taken together, our studies underscore the importance of structural diversity in achieving cancer cell type specific drug development.

17 June 2015 in Molbank
Verified
Journal Article
Open access
PDF file
RKRavil Khaybullin
Ravil Khaybullin
XLXiao Liang
Xiao Liang
XQXin Qi
Xin Qi
Aminoacyl sulfamides represent a family of high-affinity inhibitors of the specific aminoacyl tRNA synthetase activity. In this paper we describe the synthesis of a novel sulfamide adenosine derivative 4 bearing pyroglutamyl fragment (pGlu-SA).